Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Other Operating Expense : $-9.1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Other Operating Expense?

Arcturus Therapeutics Holdings's Other Operating Expense for the three months ended in Dec. 2023 was $-5.8 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.1 Mil.

Arcturus Therapeutics Holdings's quarterly Other Operating Expense declined from Jun. 2023 ($-1.0 Mil) to Sep. 2023 ($-1.8 Mil) and declined from Sep. 2023 ($-1.8 Mil) to Dec. 2023 ($-5.8 Mil).

Arcturus Therapeutics Holdings's annual Other Operating Expense declined from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($-0.2 Mil) and declined from Dec. 2022 ($-0.2 Mil) to Dec. 2023 ($-9.1 Mil).

Arcturus Therapeutics Holdings Other Operating Expense Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Other Operating Expense Chart

Arcturus Therapeutics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

-0.24

-9.05

Arcturus Therapeutics Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Operating Expense	Get a 7-Day Free Trial															-0.24	-0.56	-0.95	-1.76	-5.78

Arcturus Therapeutics Holdings Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.1 Mil.

Arcturus Therapeutics Holdings Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121

Website

https://www.arcturusrx.com

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Executives

Pad Chivukula	officer: Chief Scientific Officer & COO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld	officer: See Remarks	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne	director, 10 percent owner, officer: President and CEO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc.	director, 10 percent owner	60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata	officer: Chief Legal Officer	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine	officer: Chief Financial Officer	82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes	officer: Chief Development Officer	6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow	director	2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes	director	C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949